ABUS Arbutus Biopharma Corporation - Common Stock
$5,01
Cena · Sie 19, 2026
Dane fundamentalne na dzień Sie 12, 2026
Zakres 52 tyg.
$3–$5
82% of range
Ocena Analityków
BUY
8 analysts
Cena Docelowa
$6
+10% upside
P/E (TTM)
-30.1
ROE
-42.0%
Marża Zysku Netto
-237.9%
O Arbutus Biopharma Corporation - Common Stock Przegląd firmy z Wikipedii
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Czytaj więcej
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
ABUS Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$5.01
Kapitalizacja Rynkowa
$987M
P/E (TTM)
-30.1
EPS (TTM)
$-0.17
Przychody (TTM)
$14M
Stopa dywidendy
—
ROE
-42.0%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$3 – $5
ABUS Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$14M
2016-12-31
→
2025-12-31
EPS
$-0.17
2016-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-40M
2016-12-31
→
2025-12-31
Marże
-237.9%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
ABUS
Mediana porównawcza
P/E (TTM)
-30.1
6.7
P/S (TTM)
70.1
39.8
P/B
12.9
4.8
Price / FCF (Cena / FCF)
-24.9
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
ABUS
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-271.0%
—
Net Profit Margin (Marża Zysku Netto)
-237.9%
-220.1%
ROA
-29.6%
-35.0%
ROE
-42.0%
-43.2%
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
ABUS
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
15.7
9.7
Quick Ratio (Wskaźnik Szybkości)
15.5
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
ABUS
Mediana porównawcza
Revenue YoY (Przychody R/R)
128.2%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
-28.8%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
15.3%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
ABUS
Mediana porównawcza
ABUS Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
8 analityków
- Mocne kupno 3 37,5%
- Kup 4 50,0%
- Trzymaj 1 12,5%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
1 analityków · 2026-08-17
Niski
$5.53
Wysoki
$5.53
Średni cel
$5.53
+10,3%
Średnia cel
$5.53
+10,3%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.01%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 31 marca 2026 | $-0.05 | $-0.03 | -0.02% |
| 31 grudnia 2025 | $-0.02 | $-0.04 | 0.02% |
| 30 września 2025 | $-0.04 | $-0.03 | -0.01% |
| 30 czerwca 2025 | $0.01 | $-0.05 | 0.06% |
| 31 marca 2025 | $-0.13 | $-0.11 | -0.02% |
| 31 grudnia 2024 | $-0.07 | $-0.08 | 0.01% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Bilans 25
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Przepływy pieniężne 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Płynność i wypłacalność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Efektywność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | -382,437,717 | 191,778,950 | 191,551,282 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | -383,286,168 | 191,778,950 | 192,399,733 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Bilans 22
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Przepływy pieniężne 11
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Płynność i wypłacalność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Efektywność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $191M | $192M | · | $14M | $16M | $6M | · | $9M | $13M | $18M | · | $22M | $32M | $39M | · | $36M | |
| Net Income TTM | $159M | $140M | · | $-49M | $-62M | $-82M | · | $-77M | $-75M | $-71M | · | $-71M | $-65M | $-64M | · | $-67M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 5.9 | 6.3 | · | -17.5 | -9.4 | -7.9 | · | -9.0 | -7.2 | -6.1 | · | -4.6 | -5.5 | -7.0 | · | -3.4 | |
| P/S | 5.0 | 4.6 | · | 60.6 | 38.0 | 105.1 | · | 78.8 | 46.4 | 26.5 | · | 15.5 | 12.2 | 12.7 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| P / FCF | · | · | · | · | · | -49.9 | · | · | · | -24.0 | · | · | · | -18.2 | · | · | |
| Earnings Yield | 16.9% | 15.8% | · | -5.7% | -10.7% | -12.6% | · | -11.2% | -13.9% | -16.3% | · | -21.7% | -18.3% | -14.2% | · | -29.8% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $14M | $6M | $18M | $39M | $11M |
| Marża Operacyjna % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Zysk netto | $-34M | $-70M | $-73M | $-69M | $-76M |
| Rozwodniony EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Wskaźnik Szybkości | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-40M | $-65M | $-87M | $-36M | $-68M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 191 emitentów · $496.0M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 41 (+15 vs poprzedni kw.) | 22 (-8 vs poprzedni kw.) | 55 (+10 vs poprzedni kw.) | 44 (-8 vs poprzedni kw.) | +14.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Two Seas Capital LP | $91 658 798 | 19 095 583 | 18,48% | Akcje |
| Whitefort Capital Management, LP | $75 812 453 | 15 794 261 | 15,28% | Akcje |
| VANGUARD GROUP INC | $38 412 670 | 7 986 002 | 7,74% | Akcje |
| STATE STREET CORP | $37 772 059 | 7 869 179 | 7,62% | Akcje |
| Rubric Capital Management LP | $36 158 098 | 7 532 937 | 7,29% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $33 651 259 | 7 010 679 | 6,78% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $16 983 987 | 3 537 471 | 3,42% | Akcje |
| BlackBarn Capital Partners LP | $12 000 000 | 2 500 000 | 2,42% | Akcje |
| Woodline Partners LP | $10 952 909 | 2 281 856 | 2,21% | Akcje |
| GOLDMAN SACHS GROUP INC | $8 545 829 | 1 780 381 | 1,72% | Akcje |
| Jefferies Financial Group Inc. | $8 216 026 | 1 711 672 | 1,66% | Akcje |
| NOMURA HOLDINGS INC | $7 857 989 | 1 637 081 | 1,58% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7 398 998 | 1 541 458 | 1,49% | Akcje |
| BANK OF AMERICA CORP /DE/ | $7 169 851 | 1 493 719 | 1,45% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6 869 846 | 1 431 218 | 1,38% | Akcje |
| OSAIC HOLDINGS, INC. | $6 469 756 | 1 347 866 | 1,30% | Akcje |
| ADAR1 Capital Management, LLC | $6 087 106 | 1 268 147 | 1,23% | Akcje |
| Deltroit Asset Management (UK) LLP | $5 760 000 | 1 200 000 | 1,16% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $5 449 738 | 1 135 362 | 1,10% | Akcje |
| CITIGROUP INC | $4 175 784 | 869 955 | 0,84% | Akcje |
| BANK OF MONTREAL /CAN/ | $3 734 102 | 777 938 | 0,75% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3 123 360 | 650 700 | 0,63% | Akcje |
| MACKENZIE FINANCIAL CORP | $2 946 269 | 613 806 | 0,59% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2 889 638 | 602 008 | 0,58% | Akcje |
| Western Standard LLC | $2 605 378 | 542 787 | 0,53% | Akcje |
| Rangeley Capital, LLC | $2 400 000 | 500 000 | 0,48% | Akcje |
| Man Group plc | $2 272 642 | 473 467 | 0,46% | Akcje |
| Corbin Capital Partners, L.P. | $2 231 732 | 682 487 | 0,45% | Akcje |
| CenterBook Partners LP | $2 136 725 | 445 151 | 0,43% | Akcje |
| Freestone Capital Holdings, LLC | $2 124 000 | 442 500 | 0,43% | Akcje |
| CITADEL ADVISORS LLC | $1 942 541 | 404 696 | 0,39% | Akcje |
| KENNEDY CAPITAL MANAGEMENT LLC | $1 849 430 | 385 298 | 0,37% | Akcje |
| Swiss National Bank | $1 375 200 | 286 500 | 0,28% | Akcje |
| Ledgewood Wealth Advisors, LLC | $1 336 493 | 278 436 | 0,27% | Akcje |
| FMR LLC | $1 277 232 | 266 090 | 0,26% | Akcje |
| Susquehanna Portfolio Strategies, LLC | $1 265 688 | 263 685 | 0,26% | Akcje |
| Carrera Capital Advisors | $1 234 402 | 257 167 | 0,25% | Akcje |
| Quinn Opportunity Partners LLC | $1 225 027 | 255 214 | 0,25% | Akcje |
| D. E. Shaw & Co., Inc. | $1 209 614 | 252 003 | 0,24% | Akcje |
| STATE OF WISCONSIN INVESTMENT BOARD | $1 161 682 | 242 017 | 0,23% | Akcje |
| Campbell & CO Investment Adviser LLC | $1 106 563 | 230 534 | 0,22% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 080 475 | 225 099 | 0,22% | Akcje |
| Squarepoint Ops LLC | $999 096 | 208 145 | 0,20% | Akcje |
| MARTINGALE ASSET MANAGEMENT L P | $926 880 | 193 100 | 0,19% | Akcje |
| RHUMBLINE ADVISERS | $909 224 | 189 423 | 0,18% | Akcje |
| STRS OHIO | $810 720 | 168 900 | 0,16% | Akcje |
| Bank of New York Mellon Corp | $801 067 | 166 889 | 0,16% | Akcje |
| Caption Management, LLC | $720 000 | 150 000 | 0,15% | Opcja kupna |
| Caption Management, LLC | $720 000 | 150 000 | 0,15% | Opcja sprzedaży |
| Hudson Bay Capital Management LP | $720 000 | 150 000 | 0,15% | Akcje |
| Wealth Management Associates, Inc. | $710 376 | 147 995 | 0,14% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $701 467 | 146 139 | 0,14% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $643 433 | 142 985 | 0,13% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $631 080 | 140 240 | 0,13% | Akcje |
| Connor, Clark & Lunn Investment Management Ltd. | $619 685 | 129 101 | 0,12% | Akcje |
| BlackRock, Inc. | $567 398 | 118 208 | 0,11% | Akcje |
| Front Row Advisors LLC | $516 035 | 110 500 | 0,10% | Akcje |
| BARCLAYS PLC | $499 320 | 104 025 | 0,10% | Akcje |
| Rafferty Asset Management, LLC | $490 416 | 102 170 | 0,10% | Akcje |
| MetLife Investment Management, LLC | $452 885 | 94 351 | 0,09% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $429 994 | 89 582 | 0,09% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $407 933 | 84 986 | 0,08% | Akcje |
| JBF Capital, Inc. | $385 349 | 80 281 | 0,08% | Akcje |
| Integrated Quantitative Investments LLC | $383 698 | 79 937 | 0,08% | Akcje |
| Virtus Investment Advisers, LLC | $368 674 | 76 807 | 0,07% | Akcje |
| XTX Topco Ltd | $365 808 | 76 210 | 0,07% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $317 832 | 66 215 | 0,06% | Akcje |
| Invesco Ltd. | $305 616 | 63 670 | 0,06% | Akcje |
| Rockefeller Capital Management L.P. | $302 400 | 63 000 | 0,06% | Akcje |
| Creative Planning | $298 133 | 62 111 | 0,06% | Akcje |
| JANUS HENDERSON GROUP PLC | $273 746 | 60 900 | 0,06% | Akcje |
| Quantinno Capital Management LP | $273 413 | 56 961 | 0,06% | Akcje |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $265 118 | 55 233 | 0,05% | Akcje |
| Vanguard Global Advisers, LLC | $264 730 | 55 152 | 0,05% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $255 936 | 53 320 | 0,05% | Akcje |
| Jump Financial, LLC | $255 178 | 53 162 | 0,05% | Akcje |
| PROFUND ADVISORS LLC | $254 482 | 53 017 | 0,05% | Akcje |
| WOLVERINE TRADING, LLC | $248 868 | 55 800 | 0,05% | Opcja kupna |
| Police & Firemen's Retirement System of New Jersey | $248 203 | 51 709 | 0,05% | Akcje |
| Exome Asset Management LLC | $240 797 | 50 166 | 0,05% | Akcje |
| Magnetar Financial LLC | $225 922 | 47 067 | 0,05% | Akcje |
| State of New Jersey Common Pension Fund D | $221 602 | 46 167 | 0,04% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $212 664 | 44 305 | 0,04% | Akcje |
| ALLSTATE CORP | $212 285 | 44 226 | 0,04% | Akcje |
| Quadrature Capital Ltd | $201 619 | 42 004 | 0,04% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $189 475 | 39 474 | 0,04% | Akcje |
| ARIZONA STATE RETIREMENT SYSTEM | $189 110 | 39 398 | 0,04% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $175 680 | 36 600 | 0,04% | Opcja kupna |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $171 936 | 35 820 | 0,03% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $169 286 | 35 268 | 0,03% | Akcje |
| INTECH INVESTMENT MANAGEMENT LLC | $167 208 | 34 835 | 0,03% | Akcje |
| Mitsubishi UFJ Trust & Banking Corp | $152 102 | 31 688 | 0,03% | Akcje |
| VOYA INVESTMENT MANAGEMENT LLC | $151 070 | 31 473 | 0,03% | Akcje |
| China Universal Asset Management Co., Ltd. | $150 902 | 31 438 | 0,03% | Akcje |
| Vanguard Investments Australia, Ltd. | $150 182 | 31 288 | 0,03% | Akcje |
| KLP KAPITALFORVALTNING AS | $148 320 | 30 900 | 0,03% | Akcje |
| Premier Path Wealth Partners, LLC | $144 000 | 30 000 | 0,03% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $139 675 | 29 099 | 0,03% | Akcje |
| SHERBROOKE PARK ADVISERS LLC | $134 627 | 27 989 | 0,03% | Akcje |
| EntryPoint Capital, LLC | $134 112 | 27 940 | 0,03% | Akcje |
Insiderzy spółki 25 insiderów · 13 dyrektorzy generalni · 11 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| William H. Collier | President and CEO | 24 czerwca 2019 A | — | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 marca 2019 A | 341 396 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 1 marca 2019 A | — | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 marca 2017 A | — | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 1 marca 2019 A | — | 0 | 0 | $0 |
| Elizabeth Howard | Executive VP & General Counsel | 1 marca 2019 A | — | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Chief Business Officer | 1 marca 2019 A | — | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 marca 2019 A | 1 503 403 | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 grudnia 2018 A | — | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 kwietnia 2018 A | — | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 marca 2017 A | — | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 sierpnia 2016 M | 42 097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 marca 2016 A | — | 0 | 0 | $0 |
| Roger Sawhney | Dyrektor | 8 czerwca 2026 A | — | 0 | 0 | $0 |
| Robert A Beardsley | Dyrektor | 8 czerwca 2026 A | — | 0 | 0 | $0 |
| Frank Torti | Dyrektor | 26 listopada 2018 A | — | 0 | 0 | $0 |
| Vivek Ramaswamy | Dyrektor | 19 czerwca 2018 A | — | 0 | 0 | $0 |
| Keith S Manchester | Dyrektor | 19 czerwca 2018 A | — | 0 | 0 | $0 |
| Daniel D Burgess | Dyrektor | 19 czerwca 2018 A | — | 0 | 0 | $0 |
| Herbert J Conrad | Dyrektor | 19 czerwca 2018 A | — | 0 | 0 | $0 |
| Richard C Henriques JR | Dyrektor | 19 czerwca 2018 A | 1 000 | 0 | 0 | $0 |
| Frank Karbe | Dyrektor | 21 czerwca 2017 A | — | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Posiadacz 10% | 18 października 2021 C | 38 847 462 | 0 | 0 | $0 |
| Andrew Lo | Posiadacz 10% | 12 stycznia 2018 P | — | 0 | 0 | $0 |
| Patrick Machado | Posiadacz 10% | 12 stycznia 2018 P | — | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 8 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 zgłoszenia | 28 kwietnia 2026 | 8,00% | Aneks | — | SEC |
| Roivant Sciences Ltd. ×14 zgłoszenia | 25 lutego 2025 | 20,50% | Aneks | — | SEC |
| Patrick Machado ×4 zgłoszenia | 17 lipca 2019 | — | Pierwotne zgłoszenie | — | SEC |
| Dr. Andrew Lo ×5 zgłoszenia | 17 lipca 2019 | — | Pierwotne zgłoszenie | — | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 zgłoszenia | 12 lipca 2019 | — | Pierwotne zgłoszenie | — | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 zgłoszenia | 12 lipca 2019 | — | Pierwotne zgłoszenie | — | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 zgłoszenia | 12 lipca 2019 | — | Pierwotne zgłoszenie | — | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 zgłoszenia | 12 lipca 2019 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 34 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,66% | 58 600 NS | 30 kwietnia 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,50% | 24 523 SH | 8 sierpnia 2026 | Dziennie |
| IWC · iShares Trust | 0,17% | 546 359 SH | 8 sierpnia 2026 | Dziennie |
| LABU · Direxion Shares ETF Trust | 0,11% | 132 235 NS | 30 kwietnia 2026 | N-PORT |
| SMMV · iShares Trust | 0,10% | 62 236 SH | 8 sierpnia 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,06% | 10 748 SH | 8 sierpnia 2026 | Dziennie |
| IBB · iShares Trust | 0,06% | 1 164 301 SH | 8 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,05% | 172 487 SH | 8 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | 0,04% | 1 441 824 SH | 8 sierpnia 2026 | Dziennie |
| BIB · ProShares Trust | 0,04% | 7 110 NS | 31 maja 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,03% | 64 366 NS | 31 maja 2026 | N-PORT |
| IWM · iShares Trust | 0,02% | 4 026 921 SH | 8 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 925 044 SH | 8 sierpnia 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 122 366 SH | 8 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,02% | 65 520 NS | 30 kwietnia 2026 | N-PORT |
| ITWO · ProShares Trust | 0,02% | 7 126 NS | 31 maja 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 734 401 NS | 31 maja 2026 | N-PORT |
| ISCG · iShares Trust | 0,01% | 24 628 SH | 8 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | 0,01% | 6 673 SH | 8 sierpnia 2026 | Dziennie |
| UWM · ProShares Trust | 0,01% | 5 554 NS | 31 maja 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1 810 587 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,01% | 430 244 SH | 8 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 64 437 NS | 30 kwietnia 2026 | N-PORT |
| ISCV · iShares Trust | 0,01% | 13 314 SH | 8 sierpnia 2026 | Dziennie |
| WSML · iShares Trust | 0,01% | 11 503 SH | 8 sierpnia 2026 | Dziennie |
| URTY · ProShares Trust | 0,01% | 5 639 NS | 31 maja 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 5 309 NS | 31 maja 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 141 NS | 31 maja 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 266 009 SH | 8 sierpnia 2026 | Dziennie |
| IWV · iShares Trust | 0,00% | 49 253 SH | 8 sierpnia 2026 | Dziennie |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 86 163 NS | 31 maja 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 4 760 NS | 31 maja 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5 034 547 SH | 8 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13 683 SH | 8 sierpnia 2026 | Dziennie |